179 related articles for article (PubMed ID: 28659656)
41. Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Santin AD; Diamandis EP; Bellone S; Soosaipillai A; Cane S; Palmieri M; Burnett A; Roman JJ; Pecorelli S
Clin Cancer Res; 2005 May; 11(9):3320-5. PubMed ID: 15867230
[TBL] [Abstract][Full Text] [Related]
42. Molecular cues on obesity signals, tumor markers and endometrial cancer.
Daley-Brown D; Oprea-Ilies GM; Lee R; Pattillo R; Gonzalez-Perez RR
Horm Mol Biol Clin Investig; 2015 Jan; 21(1):89-106. PubMed ID: 25781554
[TBL] [Abstract][Full Text] [Related]
43. Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
Simpkins F; Papadia A; Kunos C; Michener C; Frasure H; AbuShahin F; Mariani A; Bakkum-Gamez JN; Landrum L; Moore K; Thomas SG; Windhorn A; Rose PG
Int J Gynecol Cancer; 2013 Jan; 23(1):98-104. PubMed ID: 23221731
[TBL] [Abstract][Full Text] [Related]
44. Pathological findings in early-stage endometrial cancer.
Zehavi S; Schneider D; Bukovsky I; Halperin R
Eur J Gynaecol Oncol; 2003; 24(1):18-20. PubMed ID: 12691310
[TBL] [Abstract][Full Text] [Related]
45. High-grade endometrial carcinomas - strategies for typing.
Soslow RA
Histopathology; 2013 Jan; 62(1):89-110. PubMed ID: 23240672
[TBL] [Abstract][Full Text] [Related]
46. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
[TBL] [Abstract][Full Text] [Related]
47. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
48. Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers.
Xiong Y; Dowdy SC; Xue A; Shujuan J; Eberhardt NL; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Mar; 96(3):601-9. PubMed ID: 15721400
[TBL] [Abstract][Full Text] [Related]
49. Clinicopathologic characteristics and outcomes of endometrial Cancer patients with mismatch repair deficiency in the era of universal Lynch syndrome screening.
Carr C; Son J; Yao M; Priyadarshini A; Marquard J; Vargas R; Michener C; AlHilli MM
Gynecol Oncol; 2020 Dec; 159(3):712-720. PubMed ID: 33046272
[TBL] [Abstract][Full Text] [Related]
50. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
51. Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer.
Tsujiura M; Mazack V; Sudol M; Kaspar HG; Nash J; Carey DJ; Gogoi R
PLoS One; 2014; 9(6):e100974. PubMed ID: 24972085
[TBL] [Abstract][Full Text] [Related]
52. DJ-1 in endometrial cancer: a possible biomarker to improve differential diagnosis between subtypes.
Morelli M; Scumaci D; Di Cello A; Venturella R; Donato G; Faniello MC; Quaresima B; Cuda G; Zullo F; Costanzo F
Int J Gynecol Cancer; 2014 May; 24(4):649-58. PubMed ID: 24614826
[TBL] [Abstract][Full Text] [Related]
53. Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.
Ramalingam P; Masand RP; Euscher ED; Malpica A
Int J Gynecol Pathol; 2016 Sep; 35(5):410-8. PubMed ID: 26598976
[TBL] [Abstract][Full Text] [Related]
54. Cooperation between p53 and the telomere-protecting shelterin component Pot1a in endometrial carcinogenesis.
Akbay EA; Peña CG; Ruder D; Michel JA; Nakada Y; Pathak S; Multani AS; Chang S; Castrillon DH
Oncogene; 2013 Apr; 32(17):2211-9. PubMed ID: 22689059
[TBL] [Abstract][Full Text] [Related]
55. Verification of microRNA expression in human endometrial adenocarcinoma.
Jurcevic S; Klinga-Levan K; Olsson B; Ejeskär K
BMC Cancer; 2016 Apr; 16():261. PubMed ID: 27039384
[TBL] [Abstract][Full Text] [Related]
56. Microsatellite instability analysis in uterine cavity washings as a screening tool for endometrial cancer in Lynch syndrome.
Bouquier J; Blons H; Narjoz C; Lécuru F; Laurent-Puig P; Bats AS
Fam Cancer; 2011 Dec; 10(4):655-7. PubMed ID: 21822721
[TBL] [Abstract][Full Text] [Related]
57. ATX‑LPA axis facilitates estrogen‑induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway.
Zhang G; Cheng Y; Zhang Q; Li X; Zhou J; Wang J; Wei L
Mol Med Rep; 2018 Mar; 17(3):4245-4252. PubMed ID: 29328374
[TBL] [Abstract][Full Text] [Related]
58. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
[TBL] [Abstract][Full Text] [Related]
59. Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level.
Gómez R; Castro A; Martínez J; Rodríguez-García V; Burgués O; Tarín JJ; Cano A
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29932437
[TBL] [Abstract][Full Text] [Related]
60. Use of mutation profiles to refine the classification of endometrial carcinomas.
McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
